Latest News and Press Releases

SYDNEY, AUSTRALIA, May 20, 2021 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy...

AIPAC reaches ~72% of events and TACTI-002 recruitment is progressing wellNew data from TACTI-002 and INSIGHT-004 to be reported at ASCO in June 2021TACTI-003 clinical trial design enables evaluation...

SYDNEY, Australia, April 28, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), the leading developer of LAG-3 related immunotherapy treatments for...

Highlights Safely dosed the last HNSCC patient for Stage 2 of Part C of the TACTI-002 Phase II study (also designated KEYNOTE-798)Initiated enrolment of first line NSCLC patients for the expansion...

SYDNEY, AUSTRALIA, April 16, 2021 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”), is pleased to announce that it has received a A$1,155,055 cash rebate...

Fast Track designation opens the potential for expedited development and review with the US FDAFast Track was granted based on the promising data package from Immutep, including from Immutep’s Phase...

Sydney, AUSTRALIA, April 07, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for...

Sydney, AUSTRALIA, March 17, 2021 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for...

New Phase IIb trial called TACTI-003, to evaluate eftilagimod alpha in combination with MSD’s KEYTRUDA® (pembrolizumab) in 1st line head and neck squamous cell carcinoma (HNSCC)HNSCC is one of the...

Sydney, AUSTRALIA, March 09, 2021 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for...